Interestingly, Tebben et al. [16] report that no patients with ovarian cancer and elevated FGF23 concentrations had hypophosphatemia, suggesting that this increase in FGF23 should be intended in this context more as a marker of disease progression rather than a TIO-related condition. The gene discussed is FGF23; the disease is ovarian carcinoma.